Mereo BioPharma Group plc (MAH0) — Cash Flow-to-Debt Ratio
Mereo BioPharma Group plc (MAH0) has a Cash Flow-to-Debt Ratio of -1.54x as of December 2025, meaning its operating cash flow of €-7.68 Million could theoretically repay -2% of its total liabilities (€5.00 Million) in one year. See financial agility of Mereo BioPharma Group plc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Mereo BioPharma Group plc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Mereo BioPharma Group plc across 10 annual periods. For the full cash flow conversion analysis, see Mereo BioPharma Group plc cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Mereo BioPharma Group plc (2016–2025)
Year-by-year debt coverage analysis for Mereo BioPharma Group plc. Check how high is Mereo BioPharma Group plc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.19x | €-30.97 Million | €5.00 Million | ▼ -190.9% |
| 2024 | -2.13x | €-32.83 Million | €15.42 Million | ▼ -60.8% |
| 2023 | -1.32x | €-21.13 Million | €15.96 Million | ▲ +10.6% |
| 2022 | -1.48x | €-38.82 Million | €26.21 Million | ▼ -986.0% |
| 2021 | -0.14x | €-5.24 Million | €38.41 Million | ▲ +62.5% |
| 2020 | -0.36x | €-28.34 Million | €77.92 Million | ▲ +63.4% |
| 2019 | -0.99x | €-45.93 Million | €46.19 Million | ▼ -48.3% |
| 2018 | -0.67x | €-23.14 Million | €34.51 Million | ▲ +29.4% |
| 2017 | -0.95x | €-32.15 Million | €33.85 Million | ▲ +76.0% |
| 2016 | -3.95x | €-29.66 Million | €7.51 Million | — |